Related Experiment Video
Updated: Dec 11, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations
Steven B Bradfute1, Chunyan Ye1, Elizabeth C Clarke1
1Center for Global Health, Department of Internal Medicine, School of Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA.
Abstract:
We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19.
More Related Videos
Related Concept Videos
Antimicrobial Effectiveness
Antibiotic Selection

